^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

BIRC3 (Baculoviral IAP repeat containing 3)

i
Other names: BIRC3, API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49, Baculoviral IAP repeat containing 3
1d
Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients. (PubMed, Ann Hematol)
Furthermore, we also used Kaplan-Meier curves, multivariate analysis and penalized Cox regression model to identify six genes (C2CD5, CD163, JADE3, BIRC3, TMEM200A, and LINC00877) related to the prognosis of DLBCL. In conclusion, we developed a machine learning model integrating clinical characteristics and gene expression profiles, providing a reliable decision-support tool for DLBCL prognosis and treatment selection.
Journal
|
BIRC3 (Baculoviral IAP repeat containing 3) • CD163 (CD163 Molecule) • TMEM200A (Transmembrane Protein 200A)
4d
Triazole-substituted pyrazole-pyrimidine hybrids as anticancer agents: synthesis, cytotoxicity, apoptosis mechanisms, and JAB1-targeted structure-based design. (PubMed, Bioorg Chem)
In parallel, binary QSAR models were developed using the MetaCore/MetaDrug platform to predict anticancer activity. Based on the combined docking and QSAR analyses, several promising analogues were identified and proposed for synthesis and subsequent biological evaluation in future studies.
Journal
|
BIRC3 (Baculoviral IAP repeat containing 3)
16d
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • CD20 positive • TP53 wild-type
|
Imbruvica (ibrutinib)
19d
Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets. (PubMed, PeerJ)
Recent studies indicate that multiple Ubiquitin-Specific Proteases (USP) family members play pivotal roles in lung cancer: Ubiquitin-Specific Peptidase 7 (USP7) promotes proliferation and osimertinib resistance in non-small cell lung cancer by stabilising proteins such as ERβ, c-Abl, and KRAS; Ubiquitin-Specific Peptidase 9, X-linked (USP9X) mediates radiotherapy resistance by regulating KDM4C and REV1; USP10 influences cellular metabolism and chemotherapy sensitivity via PTEN/AKT/mTOR and HDAC6 pathways; Ubiquitin-Specific Peptidase 14 (USP14) enhances tumour migration by regulating β-catenin and Acf7 stability; Ubiquitin-Specific Peptidase 22 (USP22) amplifies tumour stem cell properties and suppresses ferroptosis via EGFR and BMI1 signalling; Ubiquitin-Specific Peptidase 35 (USP35) and Ubiquitin-Specific Peptidase 38 (USP38) respectively modulate apoptosis resistance and proliferation through BIRC3 and KLF5; while Ubiquitin-Specific Peptidase 39 (USP39) influences mitochondrial metabolism via PDHA, thereby promoting tumour growth...It further explores the potential value of small-molecule inhibitors targeting USPs (such as P5091, IU1, and gentiopicroside) in reversing drug resistance, inducing apoptosis, and enhancing immunotherapy...This paper reviews the molecular mechanisms and targeting strategies of USPs in lung cancer based on a systematic literature search of PubMed and Web of Science databases. It further explores their potential applications in precision lung cancer therapy, providing theoretical foundations and directional guidance for future research.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • ABL1 (ABL proto-oncogene 1) • PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BIRC3 (Baculoviral IAP repeat containing 3) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • TGFB1 (Transforming Growth Factor Beta 1) • USP22 (Ubiquitin Specific Peptidase 22) • USP1 (Ubiquitin Specific Peptidase 1) • USP14 (Ubiquitin Specific Peptidase 14) • USP7 (Ubiquitin Specific Peptidase 7) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
|
Tagrisso (osimertinib) • P5091 • simmitinib (SYHA1817)
20d
Scorpio fuscus venom as a promising anticancer agent against colorectal cancer. (PubMed, Invest New Drugs)
Gene expression profiling demonstrated ≥ twofold changes in 51 genes, including downregulation of BAK1 and TRAF3, and upregulation of BIRC2, BIRC3, BIRC6, CASP8, TNFRSF8, TNFRSF11, and BOK. Collectively, these findings indicate that SFV exerts significant antitumor effects in colorectal cancer models and support its potential as a promising anticancer agent, warranting further mechanistic and translational investigation.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • BIRC3 (Baculoviral IAP repeat containing 3) • BIRC2 (Baculoviral IAP Repeat Containing 2) • CASP8 (Caspase 8) • BAK1 (BCL2 Antagonist/Killer 1)
26d
Optical Genome Mapping Enhances Structural Variant Detection and Refines Risk Stratification in Chronic Lymphocytic Leukemia. (PubMed, Genes (Basel))
Combining OGM and NGS analysis refined risk stratification beyond standard FISH panels and supports more precise, individualized management strategies in CLL. Prospective studies are warranted to evaluate the clinical utility of OGM-guided genomic profiling in contemporary treatment paradigms.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • BIRC3 (Baculoviral IAP repeat containing 3) • BCL3 (BCL3 Transcription Coactivator) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR16-1 (MicroRNA 16-1)
|
Chr del(11q) • IGH mutation • RB1 deletion
27d
IAP Antagonists Selectively Eliminate Therapy-Induced Senescent Cancer Cells via TNFα-Independent Apoptosis. (PubMed, Cancer Sci)
Here, we show that AZD5582 and AT406, potent antagonists of cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1 and cIAP2) and X-linked inhibitor of apoptosis protein (XIAP), selectively eliminated HCT116 and RKO cells that had undergone senescence following treatment with a chemotherapeutic agent such as trifluridine, camptothecin, or doxorubicin. At physiological concentrations, TNFα sensitized non-senescent, proliferating cancer cells, but not TIS and nutlin-3a-induced senescent cancer cells, to apoptosis in the presence of IAP antagonists. Collectively, these findings suggest that IAP antagonists could serve as effective concomitant agents to TIS-inducing chemotherapy that promotes TNFα secretion within tumors, functioning not only as TNFα-independent senolytics but also as potentiators of TNFα-mediated apoptosis in adjacent non-senescent, proliferating cancer cells.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • BIRC3 (Baculoviral IAP repeat containing 3) • CASP8 (Caspase 8) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
doxorubicin hydrochloride • AZD5582 • xevinapant (Debio 1143)
28d
Epstein-barr virus latent membrane protein 1 targets cIAP1, cIAP2 and TRAF2 for proteasomal degradation to activate the non-canonical NF-κB pathway. (PubMed, PLoS Pathog)
Overexpression of either cIAP1 or 2 impaired LMP1 TES1-mediated non-canonical NF-κB activation. Collectively, these studies suggest that LMP1 TES1 initiates non-canonical NF-κB signaling distinctly from CD40 and other host immunoreceptors, thereby highlighting a therapeutic target.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • BIRC3 (Baculoviral IAP repeat containing 3) • CD40 (CD40 Molecule)
1m
Role of Nek2 and Hec1 in HTLV-1-Infected T-Cell Lines. (PubMed, Eur J Haematol)
Aberrant expression of Nek2 and Hec1 may contribute to ATL pathogenesis.
Preclinical • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MCL1 (Myeloid cell leukemia 1) • BIRC3 (Baculoviral IAP repeat containing 3) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • CCND2 (Cyclin D2) • CDK2 (Cyclin-dependent kinase 2) • NEK2 (NIMA Related Kinase 2)
1m
Design, Synthesis, Molecular Docking, Dynamics Simulation, and Biological Evaluation of Novel Thiazolidinedione Derivatives Against Breast Cancer with Apoptosis-Inducing Activity. (PubMed, ACS Omega)
The cytotoxic activity of the synthesized compounds was evaluated against MCF-7 breast cancer cells, revealing IC50 values of 29.44 μM for PZ-9 and 17.35 μM for PZ-11, compared to 6.45 μM for the reference drug vincristine...PZ-11 is a promising TZD-based anticancer drug candidate against breast cancer cells, as determined by computational and experimental analysis. However, further validation is required through in vivo analysis to support these findings.
Journal
|
BIRC3 (Baculoviral IAP repeat containing 3) • AIF1 (Allograft Inflammatory Factor 1) • CASP10 (Caspase 10)
|
vincristine
2ms
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov)
P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting
Enrollment open
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr del(11q)
|
clonoSEQ
|
Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)